Nuvation Bio Secures $60 Million from Eisai for Taletrectinib Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy NUVB?
Nuvation Bio's stock fell 18.91% as it hit a 20-day low amid a slight decline in the Nasdaq-100 and S&P 500 indices.
The company's recent exclusive licensing agreement with Eisai grants Eisai development and commercialization rights for taletrectinib in Europe, providing Nuvation Bio with an upfront payment of approximately $60 million. This collaboration is expected to enhance the drug's global market reach and offer treatment options for patients with ROS1+ NSCLC. Additionally, Nuvation Bio could receive up to €145 million in milestone payments, significantly improving its financial outlook and supporting future research and development efforts.
This partnership not only strengthens Nuvation Bio's position in the oncology market but also highlights the potential for accelerated market access for taletrectinib, which is crucial for the company's growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVB
Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 11.38 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.620
Low
8.00
Averages
11.38
High
18.00
Current: 5.620
Low
8.00
Averages
11.38
High
18.00
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvation Bio (NUVB) Shares Hit Oversold Territory with RSI at 29.5
- Oversold Signal: Nuvation Bio (NUVB) shares have fallen to $6.315, with an RSI of 29.5, indicating that the recent heavy selling may be nearing exhaustion, thus providing potential buying opportunities for bullish investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 67.4, NUVB's oversold condition may attract investor attention, particularly in the context of overall strong market performance, highlighting its relative value appeal.
- Historical Performance: NUVB's 52-week low is $1.54 and high is $9.75, with the current trading price at $6.46, suggesting significant upside potential amidst volatility, which may attract investors looking for a rebound.
- Investor Sentiment: The current oversold status may prompt investors to reassess NUVB's potential value, especially after a significant price drop, potentially sparking renewed interest in the stock.
See More
Seeking Alpha Releases Q4 Stock Ratings, Micron and Others Rated Strong Buy
- Quant Model Performance: Seeking Alpha's Quant model has consistently outperformed the S&P 500, leveraging powerful computational capabilities and a unique 'Quantamental' analysis to enhance investor decision-making efficiency.
- Earnings Growth Expectations: FactSet estimates an 8.3% year-over-year earnings growth for the S&P 500 in Q4, which, if realized, would mark the index's tenth consecutive quarter of earnings growth, indicating market resilience and sustained corporate profitability.
- Top-Rated Stocks: According to Seeking Alpha's quant model, stocks like Micron Technology and Lumentum Holdings received a strong buy rating of 4.99, suggesting these companies excel in value, growth, and profitability metrics, potentially attracting more investor interest.
- Lowest-Rated Stocks: Stocks such as Fermi and Ørsted are rated as strong sells with quant scores as low as 1.00, reflecting a pessimistic outlook on their earnings prospects and prompting investors to reassess their portfolios.
See More
Nuvation Bio (NUVB) Reports $15.7M Q4 Revenue and $25M Milestone Payment from Nippon Kayaku
- Revenue Performance: Nuvation Bio reported preliminary Q4 IBTROZI net product revenue of $15.7 million and full-year revenue of $24.7 million for 2025, indicating stable growth potential in the market.
- Milestone Payment: The company received a $25 million milestone payment from Nippon Kayaku due to the establishment of a reimbursement price in Japan, which not only strengthens its financial position but also lays the groundwork for future market expansion.
- Cash Reserves: As of December 31, 2025, Nuvation Bio's preliminary unaudited cash, cash equivalents, and marketable securities are expected to be approximately $529.2 million, providing robust funding support for future R&D and operations.
- Market Reaction: Despite a 2.3% decline in premarket trading to $7.855, B. Riley initiated a “Buy” rating on Nuvation Bio's lead drug launch trajectory, reflecting market recognition of its long-term potential.
See More
Nuvation Bio and Eisai Sign Exclusive Collaboration, Securing $60 Million Upfront Payment
- Global Expansion Milestone: Nuvation Bio's exclusive licensing agreement with Eisai grants Eisai development and commercialization rights for taletrectinib in Europe and other regions, significantly broadening the drug's global market reach and providing treatment options for more patients with ROS1+ NSCLC.
- Substantial Financial Returns: Under the agreement, Nuvation Bio will receive €50 million (approximately $60 million) upfront, with potential for up to €145 million (approximately $170 million) in regulatory and commercial milestone payments, enhancing the company's financial stability and supporting future R&D efforts.
- Accelerated Market Access: Eisai plans to file a Marketing Authorization Application for taletrectinib in Europe in the first half of 2026, which is expected to expedite the drug's market entry in major regions, providing patients with quicker access to treatment and enhancing the company's competitiveness in the global oncology market.
- Advancement of Clinical Research: Nuvation Bio will continue to lead global development, focusing on U.S. launch activities and pivotal studies, ensuring taletrectinib's establishment as a standard of care for ROS1+ NSCLC, thereby solidifying its leadership position in the oncology drug market.
See More
Nuvation Bio and Eisai Form Strategic Collaboration to Expand Taletrectinib's Global Reach
- Global Market Expansion: Nuvation Bio's exclusive collaboration with Eisai grants Eisai development and commercialization rights for taletrectinib across Europe, the Middle East, and several other regions, which is expected to significantly enhance the drug's market coverage and sales potential.
- Financial Gains: Nuvation Bio will receive up to €195 million (approximately $230 million) in upfront and milestone payments, along with double-digit tiered royalties on sales in licensed territories, providing a substantial long-term revenue stream for the company.
- Clinical Outlook: Taletrectinib is already approved in the U.S., China, and Japan, with Eisai planning to file a Marketing Authorization Application in Europe in the first half of 2026, which is expected to further drive the drug's clinical application globally.
- Strategic Collaboration Significance: This partnership not only strengthens taletrectinib's global market position but also indicates Eisai's prioritization of it as a flagship oncology product, aiming to accelerate patient access to this important treatment option and enhance the company's competitiveness in cancer therapy.
See More
Nuvation Bio (NUVB): Reevaluating Valuation Following a 78% Increase in Share Price Over the Past Month
Nuvation Bio's Stock Performance: Nuvation Bio (NUVB) has seen a significant increase in its stock price, rising approximately 78% in the past month and over 234% year-to-date, reflecting strong investor confidence despite the inherent volatility in early-stage biotech investments.
Valuation Insights: The company's price-to-book ratio stands at 9.1 times, indicating a high valuation compared to the broader pharmaceutical industry, but appears more reasonable when compared to direct peers, suggesting potential for future revenue and earnings growth.
Risks and Future Potential: While the current valuation may seem demanding, a discounted cash flow (DCF) analysis suggests a fair value of around $31.99, indicating significant upside potential, though risks such as setbacks in the oncology pipeline could impact sentiment.
Investment Strategy Recommendations: Investors are encouraged to explore other fast-moving healthcare stocks and utilize tools like Simply Wall St’s stock screener to identify undervalued opportunities and strengthen their portfolios with a focus on cash flow and growth potential.
See More
Nuvation Bio (NUVB) Shares Hit Oversold Territory with RSI at 29.5
- Oversold Signal: Nuvation Bio (NUVB) shares have fallen to $6.315, with an RSI of 29.5, indicating that the recent heavy selling may be nearing exhaustion, thus providing potential buying opportunities for bullish investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 67.4, NUVB's oversold condition may attract investor attention, particularly in the context of overall strong market performance, highlighting its relative value appeal.
- Historical Performance: NUVB's 52-week low is $1.54 and high is $9.75, with the current trading price at $6.46, suggesting significant upside potential amidst volatility, which may attract investors looking for a rebound.
- Investor Sentiment: The current oversold status may prompt investors to reassess NUVB's potential value, especially after a significant price drop, potentially sparking renewed interest in the stock.
See More
Seeking Alpha Releases Q4 Stock Ratings, Micron and Others Rated Strong Buy
- Quant Model Performance: Seeking Alpha's Quant model has consistently outperformed the S&P 500, leveraging powerful computational capabilities and a unique 'Quantamental' analysis to enhance investor decision-making efficiency.
- Earnings Growth Expectations: FactSet estimates an 8.3% year-over-year earnings growth for the S&P 500 in Q4, which, if realized, would mark the index's tenth consecutive quarter of earnings growth, indicating market resilience and sustained corporate profitability.
- Top-Rated Stocks: According to Seeking Alpha's quant model, stocks like Micron Technology and Lumentum Holdings received a strong buy rating of 4.99, suggesting these companies excel in value, growth, and profitability metrics, potentially attracting more investor interest.
- Lowest-Rated Stocks: Stocks such as Fermi and Ørsted are rated as strong sells with quant scores as low as 1.00, reflecting a pessimistic outlook on their earnings prospects and prompting investors to reassess their portfolios.
See More
Nuvation Bio (NUVB) Reports $15.7M Q4 Revenue and $25M Milestone Payment from Nippon Kayaku
- Revenue Performance: Nuvation Bio reported preliminary Q4 IBTROZI net product revenue of $15.7 million and full-year revenue of $24.7 million for 2025, indicating stable growth potential in the market.
- Milestone Payment: The company received a $25 million milestone payment from Nippon Kayaku due to the establishment of a reimbursement price in Japan, which not only strengthens its financial position but also lays the groundwork for future market expansion.
- Cash Reserves: As of December 31, 2025, Nuvation Bio's preliminary unaudited cash, cash equivalents, and marketable securities are expected to be approximately $529.2 million, providing robust funding support for future R&D and operations.
- Market Reaction: Despite a 2.3% decline in premarket trading to $7.855, B. Riley initiated a “Buy” rating on Nuvation Bio's lead drug launch trajectory, reflecting market recognition of its long-term potential.
See More
Nuvation Bio and Eisai Sign Exclusive Collaboration, Securing $60 Million Upfront Payment
- Global Expansion Milestone: Nuvation Bio's exclusive licensing agreement with Eisai grants Eisai development and commercialization rights for taletrectinib in Europe and other regions, significantly broadening the drug's global market reach and providing treatment options for more patients with ROS1+ NSCLC.
- Substantial Financial Returns: Under the agreement, Nuvation Bio will receive €50 million (approximately $60 million) upfront, with potential for up to €145 million (approximately $170 million) in regulatory and commercial milestone payments, enhancing the company's financial stability and supporting future R&D efforts.
- Accelerated Market Access: Eisai plans to file a Marketing Authorization Application for taletrectinib in Europe in the first half of 2026, which is expected to expedite the drug's market entry in major regions, providing patients with quicker access to treatment and enhancing the company's competitiveness in the global oncology market.
- Advancement of Clinical Research: Nuvation Bio will continue to lead global development, focusing on U.S. launch activities and pivotal studies, ensuring taletrectinib's establishment as a standard of care for ROS1+ NSCLC, thereby solidifying its leadership position in the oncology drug market.
See More
Nuvation Bio and Eisai Form Strategic Collaboration to Expand Taletrectinib's Global Reach
- Global Market Expansion: Nuvation Bio's exclusive collaboration with Eisai grants Eisai development and commercialization rights for taletrectinib across Europe, the Middle East, and several other regions, which is expected to significantly enhance the drug's market coverage and sales potential.
- Financial Gains: Nuvation Bio will receive up to €195 million (approximately $230 million) in upfront and milestone payments, along with double-digit tiered royalties on sales in licensed territories, providing a substantial long-term revenue stream for the company.
- Clinical Outlook: Taletrectinib is already approved in the U.S., China, and Japan, with Eisai planning to file a Marketing Authorization Application in Europe in the first half of 2026, which is expected to further drive the drug's clinical application globally.
- Strategic Collaboration Significance: This partnership not only strengthens taletrectinib's global market position but also indicates Eisai's prioritization of it as a flagship oncology product, aiming to accelerate patient access to this important treatment option and enhance the company's competitiveness in cancer therapy.
See More
Nuvation Bio (NUVB): Reevaluating Valuation Following a 78% Increase in Share Price Over the Past Month
Nuvation Bio's Stock Performance: Nuvation Bio (NUVB) has seen a significant increase in its stock price, rising approximately 78% in the past month and over 234% year-to-date, reflecting strong investor confidence despite the inherent volatility in early-stage biotech investments.
Valuation Insights: The company's price-to-book ratio stands at 9.1 times, indicating a high valuation compared to the broader pharmaceutical industry, but appears more reasonable when compared to direct peers, suggesting potential for future revenue and earnings growth.
Risks and Future Potential: While the current valuation may seem demanding, a discounted cash flow (DCF) analysis suggests a fair value of around $31.99, indicating significant upside potential, though risks such as setbacks in the oncology pipeline could impact sentiment.
Investment Strategy Recommendations: Investors are encouraged to explore other fast-moving healthcare stocks and utilize tools like Simply Wall St’s stock screener to identify undervalued opportunities and strengthen their portfolios with a focus on cash flow and growth potential.
See More
